<DOC>
	<DOCNO>NCT02523703</DOCNO>
	<brief_summary>Multiple sclerosis ( MS ) inflammatory disease central nervous system , begin often subject age 20-40 year . In France , thanks recent study report general state MS 2006 , prevalence estimate 65.5 / 100,000 population ( 96.3 / 100,000 woman 41.9 / 100,000 men ) incidence 7.91 per 100,000 . In Lower Normandy , incidence MS estimate 4.45 / 100,000 inhabitant 60 new case per year . The primary objective pilot study ass level glutamate aspartate ( excitotoxicity marker ) repercussion clinical radiological outcome 40 patient experience event demyelinate central nervous system .</brief_summary>
	<brief_title>Excitotoxicity Markers Clinical-radiological Progression After Demyelinating Event : Prospective Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Man woman 18 60 year old . Patient one type inflammatory event Central system suggestive demyelinating disease ( multiple sclerosis , neuromyelitis optical Devic extensive myelitis ) No treatment corticosteroids less 1 month Need lumbar puncture perform etiologic Need brain MRI perform within etiologic Patient sign informed consent Secondary progressive MS Any consindication lumbar puncture Any contraindication MRI Minor patient patient major guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>